Lyric Bio Raises $6.6M to Revolutionize IVIg Production with Ultra-High-Density Bioreactors
核心洞察
Lyric Bio (搜索) closed an oversubscribed $6.6 million seed financing led by The Venture Collective (搜索) to develop next-generation biomanufacturing systems for donor-derived therapeutics.
The company's proprietary platform uses ultra-high-density 3D bioreactors with laser-printed cellular substrates to recreate human tissue environments for large-scale therapeutic production.
Lyric's technology targets 100-fold efficiency improvements in IVIg manufacturing, potentially reducing costs by 10x while delivering over 1,000 doses from a single donor.
Lyric Bio (搜索), a next-generation biomanufacturing startup, has closed an oversubscribed $6.6 million seed financing to advance its revolutionary approach to producing donor-derived therapeutics. The San Carlos-based company, spun out from Prellis Biologics (搜索), is developing ultra-high-density 3D bioreactors that recreate human tissue environments in vitro for large-scale therapeutic production.
The funding round was led by The Venture Collective (搜索), with participation from Black Diamond Ventures (搜索), Draper Associates (搜索), Lucas Venture Group, Meiji Seika Pharma (搜索), SOSV, and other investors. Christopher Ghadban, Head of Life Science Investing at The Venture Collective, emphasized the platform's potential to redefine biomanufacturing categories rather than incrementally improve existing approaches.
Breakthrough Technology Platform
Lyric Bio (搜索)'s proprietary platform integrates tissue engineering and bioreactor innovation to replicate the cell density of human tissue in controlled biomanufacturing environments. The technology uses tissue-mimicking bioreactors built on laser-printed cellular substrates that enable ultra-high-density cell growth, representing a fundamental departure from standard biomanufacturing processes.
"By matching human tissue densities in large-scale 3D cell culture, we can deliver human donor derived therapeutics from a biomanufacturing system, something the world has never seen before," said Melanie Matheu, PhD, co-founder and Chief Scientific Officer of Lyric Bio (搜索).
The company's approach has the potential to deliver more than 1,000 IVIg doses from a single donor, addressing chronic supply constraints that have long plagued the industry.
Targeting the $20 Billion IVIg Market
Lyric's initial focus centers on human immunoglobulin (IVIg and SCIg), a $20 billion therapeutic market used in treating over 100 diseases. The company is targeting 100-fold efficiency gains that could reduce costs by an order of magnitude while improving consistency, quality, and expanding patient access.
"Access to donor derived therapies like IVIg is limited, and a biomanufacturing revolution is needed to address these constraints," said Kayj Shannon, co-founder and CEO of Lyric Bio (搜索). "Lyric Bio's unique process can reduce human donor dependency by orders of magnitude, transforming patient access and industry economics."
Strategic Partnership with Meiji Seika Pharma
Japanese pharmaceutical company Meiji Seika Pharma (搜索) made a strategic equity investment in Lyric Bio (搜索) as part of the seed round. The partnership aims to accelerate early-stage development of Lyric's innovative IVIg production platform and explore donation-independent manufacturing methods to create a more resilient supply chain for plasma-derived therapeutics.
"Lyric Bio (搜索)'s manufacturing platform for IVIg production is truly groundbreaking technology and it has the potential to overcome current challenges in IVIg business," said Toshiaki Nagasato, President and Representative Director of Meiji Seika Pharma (搜索).
The collaboration will leverage Meiji's deep expertise in pharmaceutical development while supporting Lyric's mission to lower costs, broaden access, and decrease dependence on human donors for critical therapeutics.
Addressing Industry Bottlenecks
The funding will accelerate Lyric Bio (搜索)'s ongoing research and development activities and implementation of its IVIg manufacturing platform. The company's technology addresses fundamental bottlenecks in donor-derived therapeutic production that have limited patient access and driven up costs in the global healthcare system.
Standard biomanufacturing processes have proven insufficient for meeting growing demand for plasma-derived therapeutics, creating an urgent need for innovative approaches that can scale production while maintaining quality and safety standards.